Our Pipeline

Robust Pipeline Focused on Advancing ROCK Inhibitor Portfolio

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Upcoming Milestones

ROCK Portfolio

Idiopathic pulmonary fibrosis (IPF)

Phase 2a topline data –
H1 2024

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Pancreatic cancer*

Phase 1b commencement –
2024

cGvHD*

Phase 2a commencement –
2024

Fibrostenotic Crohn’s Disease

Phase 1 commencement –
H1 2024

Other Pipeline
Assets

Genetically selected MSS mCRCrnBiliary tract cancer and pancreatic cancer

Report Data – H1 2024

Potential partnership

Discoidin Domain Receptor (DDR) Inhibitor
(RXC009)

Fibrosis, cancer-associated fibrosis

IND / CTA Submission – 2025

Partnered

KRAS Inhibitor
(G12D selective and pan-KRAS)

Oncology

Sold to Jazz
Ongoing collaboration

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Oncology

Sold to Jazz

MAPK Pathway Target

Oncology

Licensed to Jazz
Ongoing collaboration

GI: Gastrointestinal; IND: Investigational new drug application; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase; cGvHD: Chronic Graft Versus Host Disease
* Would require additional funding

ROCK Portfolio
Phase 2

Idiopathic pulmonary fibrosis (IPF)

UPCOMING MILESTONES

Phase 2a topline data –
H1 2024

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Preclinical

Pancreatic cancer*

UPCOMING MILESTONES

Phase 1b commencement –
2024

Preclinical

cGvHD*

UPCOMING MILESTONES

Phase 2a commencement –
2024

Preclinical

Fibrostenotic Crohn’s Disease

UPCOMING MILESTONES

Phase 1 commencement –
H1 2024

Other Pipeline
Assets
Phase 2

Genetically selected MSS mCRCrnBiliary tract cancer and pancreatic cancer

UPCOMING MILESTONES

Report Data – H1 2024

Potential partnership

Discoidin Domain Receptor (DDR) Inhibitor
(RXC009)

Preclinical

Fibrosis, cancer-associated fibrosis

UPCOMING MILESTONES

IND / CTA Submission – 2025

Partnered

KRAS Inhibitor
(G12D selective and pan-KRAS)

Research

Oncology

UPCOMING MILESTONES

Sold to Jazz
Ongoing collaboration

Phase 1

Idiopathic pulmonary fibrosis (IPF)

UPCOMING MILESTONES

Licensed to AstraZeneca

UPCOMING MILESTONES

Sold to Jazz

MAPK Pathway Target

Research

Oncology

UPCOMING MILESTONES

Licensed to Jazz
Ongoing collaboration

GI: Gastrointestinal; IND: Investigational new drug application; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase; cGvHD: Chronic Graft Versus Host Disease
* Would require additional funding